Who Should Undergo Hereditary Genetic Testing for Cancer?
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology
Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.
Promises and Problems in Brain Cancer Therapy: What’s Hot Right Now?
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Darolutamide/ADT Improves Efficacy in Older Metastatic HSPC Population
Subgroup data from the ARASENS trial support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC regardless of age.
MCS-8, a Plant-Derived Drug, Reduces Prostate Cancer Incidence vs Placebo
Treatment with MCS-8 yielded no serious adverse effects among patients at a high risk of developing prostate cancer.
Personalized Medicine and Targeted Therapy May Hold Promise in Lung Cancer
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Radiation ± Chemotherapy Shows Worse Short-Term QOL in Cervical Cancer
Deeper short-term declines in quality of life occurred when combining cisplatin with radiation for those with intermediate-risk cervical cancer.
Blood-Based Screening Test May Increase Preclinical Lung Cancer Detection
The blood-based test detected 31% of lung cancers one year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.
Fertility-Sparing Surgery May Be Safe Despite Recurrence in Cervical Cancer
Fertility-sparing surgery showed comparable efficacy vs hysterectomy in early-stage cervical cancer, with a 5-year RFS rate of 92% vs 96.4%, respectively.
How Can Clinicians Combat Stigmas and Financial Barriers in Lung Cancer?
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Subcutaneous Mosunetuzumab Earns EU Approval in R/R Follicular Lymphoma
Pharmacokinetic data from the phase 1/2 GO29781 study support the European approval of subcutaneous mosunetuzumab in this follicular lymphoma population.
FDA OKs Pembrolizumab/Enfortumab Vedotin in Muscle Invasive Bladder Cancer
Results from the KEYNOTE-905 trial led to the approval of pembrolizumab/enfortumab vedotin in muscle invasive bladder cancer.
Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors
Partial responses and stable disease were observed with PAS-004 in patients with advanced solid tumors harboring RAS, NF1, or RAF mutations.
“De-Shackling” Biases in Oncology Care for Incarcerated Populations
Examining Neoadjuvant Chemoimmunotherapy Benefit in Stage III Lung Cancers
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
How ADCs and BiTEs Are Propelling Change in Lung Cancer
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Less Than Half of Incarcerated Population Receives Recommended Cancer Care
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
EC Approves Adjuvant Cemiplimab in CSCC at High Risk of Recurrence
Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.
FDA Accepts NDA for Zidesamtinib in Pretreated Advanced ROS1+ NSCLC
Zidesamtinib elicited positive activity in patients with advanced ROS1-positive NSCLC who previously received a ROS1 TKI in the phase 1/2 ARROS-1 trial.
Managing Chemotherapy-Induced Toxicities in Stage II/III Lung Cancers
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
The Favorable Toxicity Profile of NALIRIFOX Focuses on Hematologic/GI AEs in mPDAC
Key AEs of NALIRIFOX in NAPOLI 3 were GI- and hematologic-related, with favorable rates of neutropenia and less growth factor use vs nab-paclitaxel/gemcitabine in mPDAC.
Data Show Increased Cancer-Related Mortality in Incarcerated Population
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Elucidating Emergent Neoadjuvant Strategies for Stage I-III Lung Cancers
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Tarlatamab Earns Traditional FDA Approval in ES-SCLC
Data from the DeLLphi-304 trial support the full approval of tarlatamab in this extensive-stage small cell lung cancer population.
FDA Approves Sevabertinib in Non-Squamous NSCLC
Results from the SOHO-01 trial led to the approval of sevabertinib for patients with non-squamous NSCLC.
Olutasidenib Maintains Durable Responses in IDH1+ AML for 5 Years
Among all patients with AML enrolled in the trial who received olutasidenib, the CR or CRh rate was 35%, with 55% of responders responding within 2 months.
FDA Traditionally Approves Daratumumab Regimen in AL Amyloidosis
Based on results from the ANDROMEDA study, the FDA has given traditional approval to daratumumab and hyaluronidase-fihj plus VCd in patients with newly diagnosed light chain amyloidosis.
EU Approves Subcutaneous Pembrolizumab in All Approved Indications
The regulatory decision regarding the subcutaneous pembrolizumab formulation is based on results from the phase 3 3475A-D77 trial.
FDA OKs Selumetinib in NF1 Symptomatic, Inoperable Plexiform Neurofibromas
Results from the KOMET trial led to the approval of selumetinib in adults with NF1 symptomatic, inoperable plexiform neurofibromas.
Durvalumab/Carboplatin/Etoposide Proves Tolerable in ES-SCLC
Patients with ES-SCLC who had an ECOG performance status of 2 or 3 achieved ORRs of 52.4% and 45.5%, respectively, with the study treatment.
